睿知中国疾病研究地图
候选清单0

上海复旦大学

复旦大学附属肿瘤医院

Fudan University Shanghai Cancer Center

在本站收录的 53 种疾病中,这家医院列在其中 10 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

复旦大学附属肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma38 篇牵头论文牵头 1 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma32 篇牵头论文牵头 8 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma54 篇牵头论文牵头 2 项开放试验
  4. 胃癌Stomach cancer88 篇牵头论文牵头 17 项开放试验
  5. 脊索瘤Chordoma3 篇牵头论文
  6. 骨肉瘤Osteosarcoma6 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  8. 尤文肉瘤Ewing sarcoma4 篇牵头论文
  9. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文
  10. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、神经母细胞瘤、多发性骨髓瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 38 篇,占 1.6%。

牵头论文
38
2021–2025 年
牵头试验
15
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 7720222023: 8820232024: 121220242025: 662025

上海有 10 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 8

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
    分期
    III期
    开始
    2023-12
    登记号
    NCT06177301

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  2. 正在招募
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    分期
    I/II期
    开始
    2025-11
    登记号
    NCT07258979

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、东莞、南宁、南昌、厦门、广州、成都、昆明、杭州、桂林、江门、海口、福州、重庆、长沙、韶关

  3. 正在招募
    鼻咽癌个体化颈部预防性照射试验Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
    分期
    III期
    开始
    2025-09
    登记号
    NCT07303023

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、成都、杭州、重庆

  4. 正在招募
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    分期
    未注明
    开始
    2024-04
    登记号
    NCT06308328

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院;另有 9 家列出的医院为研究中心上海、广州、成都、深圳、珠海、韶关

  5. 正在招募
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
    分期
    II期
    开始
    2024-06
    登记号
    NCT06437522

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  6. 正在招募
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    分期
    III期
    开始
    2022-04
    登记号
    NCT05340491

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

  7. 正在招募
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    分期
    III期
    开始
    2020-03
    登记号
    NCT03907826

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

  8. 即将招募
    早期复发性鼻咽癌:手术与调强放疗(IMRT)的效果比较Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
    分期
    III期
    开始
    2021-03
    登记号
    NCT04215510

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院;另有 3 家列出的医院为研究中心上海、南昌、福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题放疗技术复发与转移诱导/同步化疗
论文中的科室放疗科影像/核医学科
牵头的论文38
  1. Autophagy-dependent sensitization effects of PARP inhibitors on recurrent nasopharyngeal carcinoma treated with carbon ion and photon irradiation.2025Acta biochimica et biophysica Sinica免费全文
  2. RAC2 drives hypoxia-mediated radiation resistance in nasopharyngeal carcinoma.2025Biochemical and biophysical research communications
  3. Pretreatment FDG PET in prognosis of locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.2025International journal of medical sciences免费全文
  4. Long-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults.2025Journal of cancer research and clinical oncology免费全文
  5. The role of 18 F-FDG PET/CT in detecting recurrence and metastasis in posttreatment nasopharyngeal carcinoma patients with elevated Epstein-Barr virus DNA.2025Nuclear medicine communications
  6. Beyond the ratio of tumor reduction: residual volume after induction chemotherapy emerges as the optimal biomarker in advanced nasopharyngeal cancer.2025Radiation oncology (London, England)免费全文
  7. Comparing long-term efficacy and safety of GP versus TPF sequential chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.2024BMC cancer免费全文
  8. Long-term outcomes after particle radiation therapy in patients with nasopharyngeal adenoid cystic carcinoma.2024BMC cancer免费全文
  9. Deletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non-metastatic stage T4 nasopharyngeal carcinoma in IMRT era.2024Cancer medicine
  10. A protocol for a randomized trial evaluating the role of carbon-ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma.2024Cancer medicine免费全文
  11. PICK1 inhibits the malignancy of nasopharyngeal carcinoma and serves as a novel prognostic marker.2024Cell death & disease免费全文
  12. Radiation-induced nasopharyngeal ulcers after re-irradiation with intensity-modulated radiotherapy in locoregional recurrent nasopharyngeal carcinoma patients: a dose-volume-outcome analysis.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  13. Nomograms containing body dose parameters for predicting survival in patients with nasopharyngeal carcinoma.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery免费全文
  14. Liquid biopsy with plasma Epstein-Barr virus DNA characterizes biological relapse for the prediction of cancer recurrence in non-disseminated nasopharyngeal carcinoma.2024European journal of cancer (Oxford, England : 1990)
  15. Survival outcomes and toxicity profiles among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) versus IMRT + carbon-ion radiotherapy: A propensity score-matched analysis.2024Head & neck
  16. Delta magnetic resonance imaging radiomics features‑based nomogram predicts long‑term efficacy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.2024Oral oncology
  17. Tumor volume instead of recurrent T category predicts clinical outcome of patients with locally recurrent nasopharyngeal carcinoma salvaged by carbon ion radiation therapy.2024Oral oncology
  18. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.2024Signal transduction and targeted therapy免费全文
  19. Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy.2023Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  20. Multi-task deep learning-based radiomic nomogram for prognostic prediction in locoregionally advanced nasopharyngeal carcinoma.2023European journal of nuclear medicine and molecular imaging免费全文
  21. Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes.2023Oral oncology
  22. Unraveling the patterns and pathways of local recurrence of nasopharyngeal carcinoma: evidence for individualized clinical target volume delineation.2023Radiation oncology (London, England)免费全文
  23. Induction chemotherapy plus re-irradiation versus re-irradiation alone in locally recurrent nasopharyngeal carcinoma: A model-based analysis.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  24. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  25. Trajectories of fear of progression in nasopharyngeal carcinoma patients receiving proton and heavy ion therapy.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  26. A qualitative exploration of fear of progression in patients with nasopharyngeal carcinoma treated with proton and heavy ion therapy.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  27. Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery免费全文
  28. Hepatic resection prolongs overall survival in the selected patients with nasopharyngeal carcinoma liver metastases.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  29. Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era.2022International journal of medical sciences免费全文
  30. Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment.2022Journal of experimental & clinical cancer research : CR免费全文
  31. Dissecting the heterogeneity of the microenvironment in primary and recurrent nasopharyngeal carcinomas using single-cell RNA sequencing.2022Oncoimmunology免费全文
  32. Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma.2022Oral oncology
  33. Predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma survivors after intensity-modulated radiotherapy.2022Radiation oncology (London, England)免费全文
  34. Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma.2021Annals of nuclear medicine
  35. Long-Term Results of Intensity-Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma: New Insight into the Value of Concurrent Chemotherapy.2021Cancer investigation
  36. Clinical characteristics and prognosis of elderly nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery免费全文
  37. Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?2021Frontiers in immunology免费全文
  38. Survival impact of increasing time to IMRT initiation following induction chemotherapy in nasopharyngeal carcinoma: A propensity score-matched analysis.2021Oral oncology
它在 ClinicalTrials.gov 上的全部试验(任何状态)34
  1. Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC正在招募NCT06177301牵头方(推断)III期2023-12 启动
  2. Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases状态不明NCT05771025牵头方(推断)不分期2023-04 启动
  3. SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma状态不明NCT04351282牵头方(推断)不分期2020-06 启动
  4. Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC状态不明NCT03366415牵头方(推断)III期2018-01 启动
  5. Radiation-associated Carotid Artery Disease in Patients With Nasopharyngeal Carcinoma状态不明NCT03568032牵头方(推断)2018-07 启动
  6. S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma已完成NCT03668366牵头方(推断)II期2013-08 启动
  7. Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC已完成NCT02012062牵头方(推断)III期2012-07 启动
  8. Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study状态不明NCT01884987牵头方(推断)2012-01 启动
  9. SOX as Salvage Treatment in Nasopharyngeal Carcinoma已终止NCT01403259牵头方(推断)II期2011-07 启动
  10. Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer状态不明NCT01614938牵头方(推断)II期2010-08 启动
  11. Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma已完成NCT03389295牵头方(推断)II期2010-01 启动
  12. Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)状态不明NCT00817583牵头方(推断)II期2009-01 启动
  13. Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma状态不明NCT00816816牵头方(推断)II期2007-02 启动
  14. Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma状态不明NCT00817258牵头方(推断)II期2007-01 启动
  15. Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma状态不明NCT00816855牵头方(推断)II期2007-02 启动
  16. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.正在招募NCT07258979研究中心I/II期2025-11 启动
  17. Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC正在招募NCT07303023研究中心III期2025-09 启动
  18. A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors正在招募NCT06437522研究中心II期2024-06 启动
  19. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis正在招募NCT06308328研究中心2024-04 启动
  20. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial正在招募NCT05340491研究中心III期2022-04 启动
  21. Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT即将招募NCT04215510研究中心III期2021-03 启动
  22. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients正在招募NCT03907826研究中心III期2020-03 启动
  23. Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)已终止NCT05721222研究中心I/II期2023-03 启动
  24. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  25. A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma已完成NCT03866967研究中心II期2019-03 启动
  26. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  27. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810状态不明NCT03260179研究中心I期2017-08 启动
  28. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  29. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma状态不明NCT02633176研究中心III期2015-01 启动
  30. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma状态不明NCT02944708研究中心III期2015-10 启动
  31. Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia已完成NCT02292368研究中心不分期2014-11 启动
  32. Xerostomia Pilot Fudan: Acupuncture for Prevention of Radiation-Induced Xerostomia状态不明NCT00862550研究中心不分期2009-03 启动
  33. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer状态不明NCT01074021研究中心III期2009-10 启动
  34. Acupuncture for Prevention of Radiation-Induced Xerostomia已完成NCT00430378研究中心不分期2007-01 启动
PubMed 以外找到的论文(未计入)45
  1. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncology论文
  2. 708P A single-arm, multicenter, prospective phase II study of tislelizumab in combination with nimotuzumab and GP induction followed by IMRT and tislelizumab plus nimotuzumab for high-risk locally advanced nasopharyngeal carcinoma (Recent D2025Annals of Oncology论文
  3. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncology论文
  4. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  5. CACA guidelines for holistic integrative management of adolescent and childhood nasopharyngeal carcinoma2025Holistic Integrative Oncology论文
  6. LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv2025Annals of Oncology会议摘要
  7. Management for Local or Regional Recurrent Nasopharyngeal Cancer2025Medical radiology书籍章节
  8. Systemic Treatment for Metastatic Nasopharyngeal Carcinoma2025Medical radiology书籍章节
  9. TransPred: A Novel 3D Deep Learning Model for Predicting Recurrence Risk of Nasopharyngeal Cancer after Radiotherapy2025International Journal of Radiation Oncology*Biology*Physics论文
  10. WITHDRAWN: 1373P Preliminary result of an open-label, single-arm, multicenter phase II study on tislelizumab combined with TP regimen induction chemotherapy followed by concurrent chemoradiotherapy with IMRT + IMCT for locally advanced naso2025Annals of Oncology撤稿
  11. WITHDRAWN: 1387P Deciphering tumor heterogeneity in advanced nasopharyngeal carcinoma (stage IVA): integrative analysis of dynamic EBV-DNA fluctuations and clinical outcomes2025Annals of Oncology撤稿
  12. WITHDRAWN: 1440TiP Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine(GX) versus tislelizumab plus gemcitabine/cisplatin(GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multic2025Annals of Oncology撤稿
  13. 847O Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial2024Annals of Oncology论文
  14. Efficacy of nimotuzumab added to concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  15. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncology会议摘要
  16. Identifying patients at high risk of recurrence by rebound of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  17. PATTERN OF TREATMENT FAILURE AMONG PATIENTS WITH RECURRENT NASOPHARYNGEAL CARCINOMA AFTER CARBON ION RE-IRRADIATION2024International Journal of Particle Therapy论文
  18. Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.2024Journal of Clinical Oncology会议摘要
  19. 718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies2023Journal for ImmunoTherapy of Cancer会议摘要
  20. A MRI-based radiomics combined prediction model for radiation-induced temporal lobe injury in nasopharyngeal carcinoma patients2023Journal of Radiation Research and Applied Sciences论文
  21. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  22. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncology会议摘要
  23. Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies2023The Oncologist论文
  24. Prognostic Value of Lymph Node-to-Primary Tumor Ratio of PET Standardized Uptake Value for Nasopharyngeal Carcinoma: A Recursive Partitioning Risk Stratification Analysis2023International Journal of Radiation Oncology*Biology*Physics论文
  25. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.2023Journal of Clinical Oncology会议摘要
  26. Radiotherapy Alone vs. Concurrent or Adjuvant Chemoradiotherapy for Nasopharyngeal Carcinoma Patients with Negative Epstein-Barr Virus DNA Post-Induction Chemotherapy2023International Journal of Radiation Oncology*Biology*Physics论文
  27. Radiotherapy alone versus concurrent or adjuvant chemoradiotherapy for nasopharyngeal carcinoma patients with negative Epstein-Barr virus DNA post-induction chemotherapy.2023Journal of Clinical Oncology会议摘要
  28. Response-adapted therapy for locally advanced nasopharyngeal carcinoma based on clinical response and circulating Epstein-Barr virus DNA level post induction chemotherapy.2023Journal of Clinical Oncology会议摘要
  29. 226MO Is induction chemotherapy beneficial in locally recurrent nasopharyngeal carcinoma before re-irradiation? A multicenter retrospective analysis2022Annals of Oncology论文
  30. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Research会议摘要
  31. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figshare数据集
  32. Anatomic distribution of local recurrence of nasopharyngeal carcinoma in the Era of IMRT: Suggestion of modification of clinical target volume delineation.2022Journal of Clinical Oncology会议摘要
  33. Clinical characteristics and long-term outcomes of individualized re-treatment in locoregionally recurrent nasopharyngeal carcinoma2022Research Square预印本
  34. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncology会议摘要
  35. Tislelizumab Rechallenge for Recurrent or Metastatic Nasopharyngeal Carcinoma (RM-NPC) Previously Treated with Another Anti-PD1 Antibody2022International Journal of Radiation Oncology*Biology*Physics论文
  36. Value of pretreatment 18F-FLT PET/CT and 18F-FDG PET/CT uptake heterogeneity for early prediction of treatment outcome in locally advanced nasopharyngeal carcinoma2022DOAJ (DOAJ: Directory of Open Access Journals)论文
  37. Willis Covered Stent Implantation for Treating Radiation Internal Carotid Blowout Syndrome in Nasopharyngeal Carcinoma2022Frontiers in Medical Case Reports论文
  38. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncology论文
  39. A Novel Machine Learning-Derived Radiomic Signature Predictive of Nasopharyngeal Necrosis to Guide Re-Radiotherapy for Recurrent Nasopharyngeal Carcinoma: A Multicentre Study2021SSRN Electronic Journal预印本
  40. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncology会议摘要
  41. Combining Images and T-Staging Information to Improve the Automatic Segmentation of Nasopharyngeal Carcinoma Tumors in MR Images2021IEEE Access论文
  42. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncology会议摘要
  43. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figshare数据集
  44. New Developments in the Management of Nasopharyngeal Carcinoma2021Springer eBooks书籍章节
  45. The Dosimetric Impact of Deep Learning-Based Auto-Segmentation of Organs at Risk on Nasopharyngeal and Rectal Cancer2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 32 篇,占 1.1%。

牵头论文
32
2021–2025 年
牵头试验
28
任何状态,ClinicalTrials.gov
牵头的开放试验
8
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 5520222023: 8820232024: 6620242025: 772025

上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
    分期
    II期
    开始
    2026-04
    登记号
    NCT07403136

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  2. 正在招募
    PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
    分期
    未注明
    开始
    2026-07
    登记号
    NCT07697859

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  3. 正在招募
    CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
    分期
    III期
    开始
    2025-02
    登记号
    NCT06964568

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  4. 正在招募
    TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
    分期
    III期
    开始
    2024-11
    登记号
    NCT06676449

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  5. 正在招募
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    分期
    未注明
    开始
    2022-07
    登记号
    NCT05443841

    年龄未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 8 家列出的医院为研究中心上海、南通、合肥、天津、泰州、石家庄、西安、郑州

  6. 正在招募
    Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
    分期
    III期
    开始
    2022-09
    登记号
    NCT06190782

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  7. 正在招募
    Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
    分期
    未注明
    开始
    2012-01
    登记号
    NCT04522687

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  8. 即将招募
    A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2023-12
    登记号
    NCT06152978

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  9. 即将招募
    Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
    分期
    未注明
    开始
    2026-09
    登记号
    NCT07769658

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:郑州大学第一附属医院;另有 5 家列出的医院为研究中心上海、天津、广州、成都、昆明、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗放疗免疫治疗
论文中的科室放疗科肿瘤内科影像/核医学科病理/检验科
牵头的论文32
  1. Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study.2025Cancer immunology, immunotherapy : CII免费全文
  2. Radiation-induced extracellular vesicles from cancer-associated fibroblasts drive oesophageal squamous cell carcinoma metastasis via the miR-193a-3p/PTEN/Akt pathway.2025Clinical and translational medicine免费全文
  3. Neoadjuvant chemoimmunotherapy cycles in locally advanced Esophageal squamous cell carcinoma: a retrospective comparison of three versus two cycles.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  4. Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial2025International journal of cancerRCT
  5. Coptisine inhibits esophageal carcinoma growth by modulating pyroptosis via inhibition of HGF/c-Met signaling.2025Naunyn-Schmiedeberg's archives of pharmacology
  6. Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma.2025Signal transduction and targeted therapy免费全文
  7. Phase II trial of radiotherapy plus Huachansu in elderly or chemotherapy-ineligible patients with locally advanced esophageal squamous cell carcinoma.2025The oncologistRCT免费全文
  8. Postoperative Radiotherapy in Curatively Resected Esophageal Squamous Cell Carcinoma With Occult Recurrent Laryngeal Nerve Lymph Node Metastasis.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  9. Prognostic value of genomic mutation signature associated with immune microenvironment in southern Chinese patients with esophageal squamous cell carcinoma.2024Cancer immunology, immunotherapy : CII免费全文
  10. The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma.2024Cancer letters
  11. Synaptotagmin 13 Could Drive the Progression of Esophageal Squamous Cell Carcinoma Through Upregulating ACRV1.2024DNA and cell biology
  12. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial.2024The lancet. Gastroenterology & hepatologyRCT
  13. Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis.2024Thoracic cancer免费全文
  14. Machine learning to predict occult metastatic lymph nodes along the recurrent laryngeal nerves in thoracic esophageal squamous cell carcinoma.2023BMC cancer免费全文
  15. Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis.2023Cancer medicine免费全文
  16. Caution against simultaneous integrated boost radiotherapy for upper thoracic esophageal squamous cell carcinoma: results from a single-arm phase II trial.2023Esophagus : official journal of the Japan Esophageal Society
  17. Precise pattern of lymphatic spread of esophageal squamous cell carcinoma: results of 1074 patients with N1 disease.2023Journal of cancer research and clinical oncology免费全文
  18. Lymphocyte recovery from radiation-induced lymphopenia in locally advanced esophageal squamous cell carcinoma: correlations with prognosis and lymphocyte-related organs.2023Radiation oncology (London, England)免费全文
  19. Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9).2023Radiation oncology (London, England)免费全文
  20. Less Irradiation to Lymphocyte-Related Organs Reduced the Risk of G4 Lymphopenia in Esophageal Cancer: Re-Analysis of Prospective Trials.2023The oncologist免费全文
  21. Extracellular shuttling miR-21 contributes to esophageal cancers and human umbilical vein endothelial cell communication in the tumor microenvironment and promotes tumor angiogenesis by targeting phosphatase and tensinhomolog.2023Thoracic cancer免费全文
  22. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.2022JAMA network openRCT免费全文
  23. Dose escalation based on 18F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12).2022Radiation oncology (London, England)RCT免费全文
  24. PD-1 Inhibitor Enhanced Radiosensitivity by Reactivating T Cells and Inducing G2/M Phase Arrest in Esophageal Squamous Cell Carcinoma.2022Radiation research
  25. Potentially functional genetic variants of the notch signaling pathway genes predict survival of Chinese patients with esophageal squamous cell carcinoma.2022The journal of gene medicine
  26. Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study.2022The oncologist免费全文
  27. Impact of post-operative serum albumin level on anastomotic leakage after transthoracic oesophagectomy for oesophageal squamous cell carcinoma.2021ANZ journal of surgery
  28. Esophageal Carcinosarcoma: Analysis of Clinical Features and Prognosis of 24 Cases and a Literature Review.2021Cancer control : journal of the Moffitt Cancer Center免费全文
  29. The superiority of [68Ga]-FAPI-04 over [18F]-FDG PET/CT in imaging metastatic esophageal squamous cell carcinoma.2021European journal of nuclear medicine and molecular imaging
  30. Local therapy for oligometastatic esophageal squamous cell carcinoma: a prospective, randomized, Phase II clinical trial.2021Future oncology (London, England)
  31. Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.2021International journal of radiation oncology, biology, physicsRCT
  32. A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11).2021The oncologist免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)39
  1. Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer正在招募NCT04522687牵头方2012-01 启动
  2. PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC正在招募NCT07697859牵头方(推断)2026-07 启动
  3. Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC正在招募NCT07403136牵头方(推断)II期2026-04 启动
  4. CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC正在招募NCT06964568牵头方(推断)III期2025-02 启动
  5. TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC正在招募NCT06676449牵头方(推断)III期2024-11 启动
  6. A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma即将招募NCT06152978牵头方(推断)II期2023-12 启动
  7. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)正在招募NCT05443841牵头方(推断)2022-07 启动
  8. Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor正在招募NCT06190782牵头方(推断)III期2022-09 启动
  9. A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.状态不明NCT05760391牵头方(推断)不分期2023-02 启动
  10. Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)状态不明NCT05281003牵头方(推断)II期2023-02 启动
  11. TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma进行中,不再招募NCT06401447牵头方(推断)不分期2023-12 启动
  12. Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma状态不明NCT05633641牵头方(推断)2022-10 启动
  13. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709牵头方(推断)2021-10 启动
  14. ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma状态不明NCT05426850牵头方(推断)2021-06 启动
  15. Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)进行中,不再招募NCT04764227牵头方(推断)II期2020-05 启动
  16. PET in Guiding Cervical Lymphadenectomy (ECTOP-2003)已完成NCT03244566牵头方(推断)2018-06 启动
  17. Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas已完成NCT03797625牵头方(推断)II期2017-05 启动
  18. SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma状态不明NCT04115618牵头方(推断)II期2017-01 启动
  19. Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02677597牵头方(推断)III期2016-01 启动
  20. Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas状态不明NCT02665702牵头方(推断)II期2016-01 启动
  21. A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer已完成NCT02459457牵头方(推断)III期2015-07 启动
  22. Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma状态不明NCT02384811牵头方(推断)II期2014-12 启动
  23. Study of S-1 in Combination With Radiotherapy in Esophageal Cancer已完成NCT01831531牵头方(推断)II期2013-03 启动
  24. A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma已完成NCT01591135牵头方(推断)III期2012-04 启动
  25. S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study已完成NCT01854749牵头方(推断)II期2011-11 启动
  26. A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer状态不明NCT01391572牵头方(推断)II期2011-04 启动
  27. Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0状态不明NCT01398449牵头方(推断)III期2011-04 启动
  28. Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy状态不明NCT01402180牵头方(推断)II/III期2010-12 启动
  29. Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma即将招募NCT07769658研究中心2026-09 启动
  30. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC状态不明NCT05221658研究中心II期2022-08 启动
  31. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  32. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  33. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  34. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  35. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  36. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  37. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  38. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  39. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma状态不明NCT01232374研究中心II期2010-09 启动
PubMed 以外找到的论文(未计入)33
  1. 474. NEOADJUVANT CHEMOIMMUNOTHERAPY VERSUS CHEMOTHERAPY PLUS ESOPHAGECTOMY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: PRIMARY RESULT OF A RANDOMIZED CLINICAL TRIAL2025Diseases of the Esophagus论文
  2. 475. COMPREHENSIVE GENOMIC AND TRANSCRIPTOMIC ANALYSES REVEAL PROGNOSTIC STRATIFICATION FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  3. 963P SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients (pts) with advanced or metastatic solid tumors: Results from dose escalation study2025Annals of Oncology论文
  4. Irradiated Tumor Cell-Derived Extracellular Vesicles Foster Immunosuppressive Macrophages Formation to Promote Esophageal Squamous Cell Carcinoma Progression2025International Journal of Radiation Oncology*Biology*Physics论文
  5. Medium dose of TPF chemotherapy with concurrent radiotherapy and immunotherapy for locally advanced esophageal squamous cell carcinoma.2025Journal of Clinical Oncology论文
  6. Radiation-Induced Extracellular Vesicles from Cancer-Associated Fibroblasts Facilitate Esophageal Squamous Cell Carcinomametastasis through the miR-193a-3p/PTEN/Akt Pathway2025International Journal of Radiation Oncology*Biology*Physics论文
  7. The combination of PD-1 inhibitor with chemotherapy ± salvage chemoradiotherapy for local primary-recurrence esophageal squamous cell carcinoma after definitive chemoradiotherapy: A prospective, multicenter, single-arm clinical study (ESO-N2025Journal of Clinical Oncology论文
  8. 1462P A pilot study of hypoxia as a potential resistance mechanism to PD-1 checkpoint blockade therapy in neoadjuvant treatment of esophageal squamous cell carcinoma (HYPERION)2024Annals of Oncology论文
  9. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  10. Maximum PET/CT 18F-FDG uptake of lymph nodes predicts prognosis in esophageal squamous cell carcinoma2024International Journal of Radiation Research论文
  11. 145. PRECISE PATTERN OF LYMPHATIC SPREAD OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA RESULTS OF 1074 PATIENTS WITH N1 DISEASE2023Diseases of the Esophagus论文
  12. A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.2023Journal of Clinical Oncology会议摘要
  13. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figshare数据集
  14. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  15. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  16. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  17. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  18. Re-irradiation of In- or Out-of-PTV Esophageal Recurrence after Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma2023Research Square预印本
  19. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncology会议摘要
  20. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study2022Annals of Oncology论文
  21. 132TiP Dose escalation of chemoradiotherapy in locally advanced esophageal squamous cell carcinoma based on positron emission tomography response: A phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)2022Annals of Oncology论文
  22. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  23. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figshare数据集
  24. P-100 CXCL8 is a valid potential prognostical marker for esophageal squamous cell carcinoma2022Annals of Oncology会议摘要
  25. Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncology会议摘要
  26. Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncology会议摘要
  27. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncology论文
  28. 667 PEGYLATED RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR IN DEFINITIVE CHEMORADIOTHERAPY OF ESOPHAGEAL CANCER: PRELIMINARY RESULTS2021Diseases of the Esophagus论文
  29. ASO Visual Abstract: Additional esophagectomy following noncurative endoscopic resection for early esophageal squamous cell carcinoma: a multicenter retrospective study2021Annals of Surgical Oncology论文
  30. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  31. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要
  32. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figshare数据集
  33. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 54 篇,占 0.4%。

牵头论文
54
2021–2025 年
牵头试验
18
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 9920222023: 9920232024: 141420242025: 13132025

上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
    分期
    II期
    开始
    2025-01
    登记号
    NCT06812039

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 2 家列出的医院为研究中心上海、天津、福州

  2. 正在招募
    Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
    分期
    II期
    开始
    2021-09
    登记号
    NCT05057845

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  3. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  4. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  5. 正在招募
    A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
    分期
    I期
    开始
    2025-06
    登记号
    NCT07376707

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  6. 即将招募
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    分期
    III期
    开始
    2025-01
    登记号
    NCT06779461

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、兰州、南京、天津、广州、蚌埠、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物局部治疗(消融、TACE、HAIC)
论文中的科室肿瘤内科病理/检验科影像/核医学科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文54
  1. ALKBH5 deficiency suppresses hepatocarcinogenesis in mice via m6A-dependent STAT1 restoration.2026Acta pharmacologica Sinica
  2. NRAV promotes HCC stemness via the m6A-regulated let-7c-5p/LIN28B axis.2026Cancer gene therapy免费全文
  3. LncRNA HOXC-AS1 Promotes Tumor Progression via miR-876-3p/NR3C1 in Hepatocellular Carcinoma.2025APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  4. A therapeutic strategy integrating ultrasound-guided microwave ablation with nanocomposite hydrogels to enhance autophagy and suppress tumor growth in hepatocellular carcinoma.2025Acta biomaterialia
  5. The liver-specific long noncoding RNA FAM99B inhibits ribosome biogenesis and cancer progression through cleavage of dead-box Helicase 21.2025Cell death & disease免费全文
  6. LTA4H improves the tumor microenvironment and prevents HCC progression via targeting the HNRNPA1/LTBP1/TGF-β axis.2025Cell reports. Medicine免费全文
  7. Efficacy of therapies for intermediate-stage hepatocellular carcinoma: systematic review and network meta-analysis.2025Frontiers in immunology免费全文
  8. Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma.2025Human vaccines & immunotherapeutics免费全文
  9. The Dichotomous Role of Tertiary Lymphoid Structures in Hepatocellular Carcinoma: From Spatial Location to Clinical Implications.2025Immunological investigations
  10. Circular RNA CDYL facilitates hepatocellular carcinoma stemness and PD-L1+ exosomes-mediated immunotherapy resistance via stabilizing hornerin protein by blocking synoviolin 1-mediated ubiquitination.2025International journal of biological macromolecules
  11. PD-1 suppresses human CD38+ circulating Tfr cells and regulates humoral immunity.2025Journal for immunotherapy of cancer免费全文
  12. Iodine-131 radioembolization boosts the immune activation enhanced by icaritin/resiquimod in hepatocellular carcinoma.2025Journal of controlled release : official journal of the Controlled Release Society
  13. SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming.2025Journal of experimental & clinical cancer research : CR免费全文
  14. Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy.2025Journal of hematology & oncology免费全文
  15. Tumor-associated macrophage-based predictive and prognostic model for hepatocellular carcinoma.2025PloS one免费全文
  16. Mutation-Selected Amplification droplet digital PCR: A new single nucleotide variant detection assay for TP53R249S mutant in tumor and plasma samples.2024Analytica chimica acta
  17. MicroRNA-148a-3p suppresses the glycolysis and Cell proliferation by targeting transmembrane protein 54 in liver cancer.2024Biochemical and biophysical research communications
  18. LTR retrotransposon-derived LncRNA LINC01446 promotes hepatocellular carcinoma progression and angiogenesis by regulating the SRPK2/SRSF1/VEGF axis.2024Cancer letters
  19. Hyperactivation of β-catenin signal in hepatocellular carcinoma recruits myeloid-derived suppressor cells through PF4-CXCR3 axis.2024Cancer letters
  20. Heat shock transcription factor 1 facilitates liver cancer progression by driving super-enhancer-mediated transcription of MYCN.2024Cancer medicine免费全文
  21. Metabolic self-feeding in HBV-associated hepatocarcinoma centered on feedback between circulation lipids and the cellular MAPK/mTOR axis.2024Cell communication and signaling : CCS免费全文
  22. Glucose-induced LINC01419 reprograms the glycolytic pathway by recruiting YBX1 to enhance PDK1 mRNA stability in hepatocellular carcinoma.2024Clinical and translational medicine免费全文
  23. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study.2024ESMO open
  24. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.2024Journal of hematology & oncology免费全文
  25. Potent induction of antitumor immunity by combining cryo-thermal ablation with immune checkpoint inhibitors in hepatocellular carcinoma.2024Liver international : official journal of the International Association for the Study of the Liver
  26. Calpain 2 promotes Lenvatinib resistance and cancer stem cell traits via both proteolysis-dependent and independent approach in hepatocellular carcinoma.2024Molecular biomedicine免费全文
  27. Spatial single-cell protein landscape reveals vimentinhigh macrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma.2024Nature cancer
  28. Elevated choline drives KLF5-dominated transcriptional reprogramming to facilitate liver cancer progression.2024Oncogene
  29. Oncofetal TRIM71 drives liver cancer carcinogenesis through remodeling CEBPA-mediated serine/glycine metabolism.2024Theranostics免费全文
  30. ASO Author Reflections: Early Recurrence in Hepatocellular Carcinoma Patients with Microvascular Invasion After Hepatectomy.2023Annals of surgical oncology
  31. A Practical Risk Classification of Early Recurrence in Hepatocellular Carcinoma Patients with Microvascular invasion after Hepatectomy: A Decision Tree Analysis.2023Annals of surgical oncology
  32. ZNF655 promotes the progression of hepatocellular carcinoma through PSMB8.2023Cell biology international
  33. TRIM14 Overexpression Induces Chemoresistance and Malignant Behaviors of Hepatocellular Carcinoma Cells by Activating the STAT3/HIF-1α Pathway.2023International journal of molecular sciences免费全文
  34. Aberrantly expressed HIF-1α enhances HCC stem cell-like traits via Wnt/β-catenin signaling activation after insufficient radiofrequency ablation.2023Journal of cancer research and therapeutics
  35. Alcohol and the mechanisms of liver disease.2023Journal of gastroenterology and hepatology
  36. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers.2023Nature communications免费全文
  37. Bufalin Inhibits Tumorigenesis and SREBP-1-Mediated Lipogenesis in Hepatocellular Carcinoma via Modulating the ATP1A1/CA2 Axis.2023The American journal of Chinese medicine
  38. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study.2023The British journal of radiology免费全文
  39. RNA binding protein RALY activates the cholesterol synthesis pathway through an MTA1 splicing switch in hepatocellular carcinoma.2022Cancer letters
  40. RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1.2022Cancer research免费全文
  41. Endothelial Nogo-B Suppresses Cancer Cell Proliferation via a Paracrine TGF-β/Smad Signaling.2022Cells免费全文
  42. A pathway-guided strategy identifies a metabolic signature for prognosis prediction and precision therapy for hepatocellular carcinoma.2022Computers in biology and medicine
  43. Hepatic resection prolongs overall survival in the selected patients with nasopharyngeal carcinoma liver metastases.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  44. LncRNA-EWSAT1 promotes hepatocellular carcinoma metastasis via activation of the Src-YAP signaling axis.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  45. Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC.2022Hepatology international
  46. The value of preoperative 18F-FDG PET metabolic and volumetric parameters in predicting microvascular invasion and postoperative recurrence of hepatocellular carcinoma.2022Nuclear medicine communications
  47. Identification of a novel Calpain-2-SRC feed-back loop as necessity for β-Catenin accumulation and signaling activation in hepatocellular carcinoma.2022Oncogene
  48. Relative Quantification of N-Glycopeptide Sialic Acid Linkage Isomers by Ion Mobility Mass Spectrometry.2021Analytical chemistry
  49. Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma.2021Bioengineered免费全文
  50. Combinatorial Normalization of Liver-Derived Cytokine Pathways Alleviates Hepatic Tumor-Associated Cachexia in Zebrafish.2021Cancer research
  51. Gain of LINC00624 Enhances Liver Cancer Progression by Disrupting the Histone Deacetylase 6/Tripartite Motif Containing 28/Zinc Finger Protein 354C Corepressor Complex.2021Hepatology (Baltimore, Md.)
  52. Baseline apparent diffusion coefficients: Validation study of new predictor of survival in patients with unresectable hepatocellular carcinoma following chemoembolization.2021Journal of X-ray science and technology
  53. Identification of miRNAs, mRNAs, lncRNAs, and circRNAs associated with hepatocellular carcinoma recurrence after interferon treatment.2021Journal of biological regulators and homeostatic agents
  54. Comprehensive analysis of N6 -methyladenosine-related long non-coding RNAs for prognosis prediction in liver hepatocellular carcinoma.2021Journal of clinical laboratory analysis免费全文
中文论文(未计入)1
  1. [The clinical value of serum GPC3 level in predicting recurrence of patients with primary hepatocellular carcinoma].2023Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
它在 ClinicalTrials.gov 上的全部试验(任何状态)45
  1. HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence正在招募NCT06812039牵头方(推断)II期2025-01 启动
  2. Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma正在招募NCT05057845牵头方(推断)II期2021-09 启动
  3. Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma状态不明NCT06441019牵头方(推断)II期2024-07 启动
  4. HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma状态不明NCT06475287牵头方(推断)II期2024-07 启动
  5. Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma状态不明NCT06285019牵头方(推断)II期2023-12 启动
  6. Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases状态不明NCT05771025牵头方(推断)不分期2023-04 启动
  7. Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma状态不明NCT05675462牵头方(推断)I期2023-03 启动
  8. Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)状态不明NCT05897268牵头方(推断)II期2023-06 启动
  9. Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors状态不明NCT06588569牵头方(推断)不分期2022-10 启动
  10. Efficacy and Safety of T+A+RAD in HCC状态不明NCT05396937牵头方(推断)II期2022-01 启动
  11. HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection状态不明NCT05311319牵头方(推断)II期2022-01 启动
  12. TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)已完成NCT04954794牵头方(推断)II期2021-07 启动
  13. Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma状态不明NCT04996459牵头方(推断)2020-03 启动
  14. TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma已完成NCT04297280牵头方(推断)II期2020-04 启动
  15. ALPPS Combined With Tislelizumab in Liver Malignancy状态不明NCT04996446牵头方(推断)II期2020-08 启动
  16. Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase状态不明NCT01715532牵头方(推断)II期2012-07 启动
  17. Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer状态不明NCT00999843牵头方(推断)I/II期2009-10 启动
  18. Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma状态不明NCT00805896牵头方(推断)II期2008-12 启动
  19. A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors正在招募NCT07376707研究中心I期2025-06 启动
  20. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  21. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  22. A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma即将招募NCT06779461研究中心III期2025-01 启动
  23. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  24. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  25. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  26. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer已终止NCT04520906研究中心不分期2020-12 启动
  27. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor进行中,不再招募NCT04008797研究中心I/II期2019-07 启动
  28. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  29. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  30. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  31. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  32. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  33. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  34. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  35. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma已完成NCT03434379研究中心III期2018-03 启动
  36. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  37. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  38. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810状态不明NCT03260179研究中心I期2017-08 启动
  39. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动
  40. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC已完成NCT03516071研究中心II期2017-05 启动
  41. A Study to Evaluate SHR-1210 in Subjects With Advanced HCC已完成NCT02989922研究中心II期2016-11 启动
  42. Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT02953743研究中心I期2016-09 启动
  43. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma已完成NCT02508467研究中心I期2015-07 启动
  44. Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma已终止NCT02267213研究中心II期2014-04 启动
  45. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma已完成NCT01988493研究中心I/II期2014-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 88 篇,占 0.9%。

牵头论文
88
2021–2025 年
牵头试验
44
任何状态,ClinicalTrials.gov
牵头的开放试验
17
正在或即将招募
作为研究中心的开放试验
21
由其他机构牵头
每年牵头的论文数
2021: 171720212022: 171720222023: 151520232024: 191920242025: 20202025

上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 38

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
    分期
    II期
    开始
    2026-01
    登记号
    NCT07492615

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  2. 正在招募
    Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
    分期
    II期
    开始
    2026-01
    登记号
    NCT07517107

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  3. 正在招募
    Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
    分期
    II期
    开始
    2025-09
    登记号
    NCT07194005

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  4. 正在招募
    The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy
    分期
    II期
    开始
    2025-11
    登记号
    NCT07757165

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  5. 正在招募
    Metronomic Capecitabine in Stage III Gastric Cancer
    分期
    III期
    开始
    2024-03
    登记号
    NCT06313567

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  6. 正在招募
    The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer
    分期
    未注明
    开始
    2024-09
    登记号
    NCT06786169

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  7. 正在招募
    The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota
    分期
    未注明
    开始
    2024-03
    登记号
    NCT07400354

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  8. 正在招募
    Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
    分期
    II期
    开始
    2023-01
    登记号
    NCT05975749

    年龄 20 岁 至 80 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  9. 正在招募
    Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
    分期
    II期
    开始
    2023-01
    登记号
    NCT06121700

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  10. 正在招募
    A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
    分期
    不分期
    开始
    2023-11
    登记号
    NCT06158919

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  11. 正在招募
    Laparoscopic vs Open Total Gastrectomy for Gastric Cancer
    分期
    不分期
    开始
    2022-10
    登记号
    NCT05537129

    年龄 20 岁 至 80 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  12. 正在招募
    Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer
    分期
    未注明
    开始
    2021-05
    登记号
    NCT04809025

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  13. 正在招募
    Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
    分期
    III期
    开始
    2021-07
    登记号
    NCT04997837

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  14. 即将招募
    A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer
    分期
    II期
    开始
    2026-10
    登记号
    NCT07878221

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  15. 即将招募
    Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
    分期
    II期
    开始
    2026-11
    登记号
    NCT07912957

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  16. 即将招募
    Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer
    分期
    II期
    开始
    2024-12
    登记号
    NCT06748508

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  17. 邀请入组
    Anemia on Sublingual Microcirculation in GDFT
    分期
    未注明
    开始
    2026-05
    登记号
    NCT07583927

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院上海

  18. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  19. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  20. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

  21. 正在招募
    A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    分期
    II期
    开始
    2025-02
    登记号
    NCT06760819

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、杭州、长沙

  22. 正在招募
    HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
    分期
    I期
    开始
    2025-05
    登记号
    NCT06769425

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  23. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  24. 正在招募
    Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
    分期
    III期
    开始
    2025-12
    登记号
    NCT07366528

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院;另有 3 家列出的医院为研究中心上海

  25. 正在招募
    A IIT Study of 177Lu-DOTA-SNA040
    分期
    早期I期
    开始
    2025-11
    登记号
    NCT07595237

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  26. 正在招募
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    分期
    不分期
    开始
    2024-09
    登记号
    NCT06128252

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 11 家列出的医院为研究中心上海、乌鲁木齐、南京、武汉、沈阳、西安、重庆

  27. 正在招募
    Early Detection and Post-operative Monitoring of Gastric Cancer
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06232395

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  28. 正在招募
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    分期
    I/II期
    开始
    2024-06
    登记号
    NCT06324357

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、南京、哈尔滨、天津、杭州、郑州、长春

  29. 正在招募
    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
    分期
    I/II期
    开始
    2024-09
    登记号
    NCT06469944

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、厦门、杭州、福州、郑州

  30. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

  31. 正在招募
    Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
    分期
    不分期
    开始
    2024-12
    登记号
    NCT06679244

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:复旦大学附属华山医院;另有 2 家列出的医院为研究中心上海

  32. 正在招募
    Post-operative Monitoring of Gastric Cancer
    分期
    未注明
    开始
    2024-02
    登记号
    NCT07026240

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  33. 正在招募
    A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
    分期
    I期
    开始
    2024-07
    登记号
    NCT07923214

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、成都、福州

  34. 正在招募
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    分期
    不分期
    开始
    2023-12
    登记号
    NCT06081647

    年龄 18 岁 至 60 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院;另有 7 家列出的医院为研究中心上海、南京、南昌、杭州、济南

  35. 正在招募
    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
    分期
    I期
    开始
    2023-11
    登记号
    NCT06131840

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、广州

  36. 即将招募
    TR115 in ARID1A-Mutated Advanced Solid Tumors
    分期
    II期
    开始
    2026-09
    登记号
    NCT07793318

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  37. 即将招募
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    分期
    未注明
    开始
    2026-10
    登记号
    NCT07902596

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省人民医院(南医大一附院);另有 6 家列出的医院为研究中心上海、南京、石家庄、苏州、青岛

  38. 即将招募
    A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
    分期
    I期
    开始
    2025-06
    登记号
    NCT07036185

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物腹膜转移与晚期手术
论文中的科室肿瘤内科病理/检验科放疗科影像/核医学科
牵头的论文88
  1. Exosomal CCT6A Secreted by Cancer-Associated Fibroblasts Interacts with β-Catenin to Enhance Chemoresistance and Tumorigenesis in Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Comparative genomic analysis of Helicobacter pylori isolates from gastric cancer and gastritis in China.2025BMC cancer免费全文
  3. Artifact reduction and diagnostic value of monoenergetic reconstructions from split-filter and dual-layer spectral detector dual-energy CT in early gastric cancer with titanium clip localization.2025BMC medical imaging免费全文
  4. FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity.2025Cancer letters
  5. PDPN+LTBP1+ cancer-associated fibroblasts induce a liver pre-metastatic niche in gastric cancer via PDPN/YAP/LTBP1 and CCL11/CCR3 axis.2025Cell communication and signaling : CCS免费全文
  6. An EBNA1-YAP signaling axis drives immune escape through CD276 in EBV-associated gastric cancer.2025Cell death & disease免费全文
  7. The value of serum tumor-associated autoantibodies in screening and diagnosis of gastric cancer.2025Clinica chimica acta; international journal of clinical chemistry
  8. Development and validation of a gastric cancer prognostic model utilizing lymphatic endothelial cell-related genes.2025Diagnostic pathology免费全文
  9. Optimizing surgical timing following neoadjuvant therapy for gastric Cancer: Insights from a multicenter retrospective analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01).2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationRCT
  11. Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models.2025International journal of nanomedicine免费全文
  12. Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset gastric cancer: A retrospective cohort study.2025Journal of advanced research免费全文
  13. Helicobacter pylori and gastric cancer: mechanisms and new perspectives.2025Journal of hematology & oncology免费全文
  14. Preclinical Evaluation of 68Ga-Labeled CSPG4-Targeting Peptides for PET/CT Imaging in Pancreatic and Gastric Carcinoma.2025Journal of medicinal chemistry免费全文
  15. BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer.2025Molecular cancer免费全文
  16. A nucleotide regulates NR4A1 status in gastric cancer.2025Molecular cell
  17. Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response.2025Nature communications免费全文
  18. Effects of Oral Nutritional Supplements in Gastric Cancer Patients with Malnutrition-Sarcopenia Syndrome.2025Nutrition and cancer
  19. USP14-IMP2-CXCL2 axis in tumor-associated macrophages facilitates resistance to anti-PD-1 therapy in gastric cancer by recruiting myeloid-derived suppressor cells.2025Oncogene
  20. An inherited predisposition allele promotes gastric cancer via enhancing deubiquitination-mediated activation of epithelial-to-mesenchymal transition signaling.2025The Journal of clinical investigation免费全文
  21. Gastric point-of-care ultrasonography in patients undergoing radical gastrointestinal surgery before anesthetic induction: an observational cohort study.2024BMC anesthesiology免费全文
  22. CC chemokine receptors are prognostic indicators of gastric cancer and are associated with immune infiltration.2024BMC medical genomics免费全文
  23. Single cell and bulk RNA sequencing identifies tumor microenvironment subtypes and chemoresistance-related IGF1+ cancer-associated fibroblast in gastric cancer.2024Biochimica et biophysica acta. Molecular basis of disease
  24. LncRNA-CCAT5-mediated crosstalk between Wnt/β-Catenin and STAT3 signaling suggests novel therapeutic approaches for metastatic gastric cancer with high Wnt activity.2024Cancer communications (London, England)免费全文
  25. SNHG15-mediated feedback loop interplays with HNRNPA1/SLC7A11/GPX4 pathway to promote gastric cancer progression.2024Cancer science免费全文
  26. LncRNA SNHG26 promotes gastric cancer progression and metastasis by inducing c-Myc protein translation and an energy metabolism positive feedback loop.2024Cell death & disease免费全文
  27. Immunosuppressive MFAP2+ cancer associated fibroblasts conferred unfavorable prognosis and therapeutic resistance in gastric cancer.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  28. Systematic Analysis of Tumor Stem Cell-related Gene Characteristics to Predict the PD-L1 Immunotherapy and Prognosis of Gastric Cancer.2024Current medicinal chemistry
  29. The distribution and maturation of tertiary lymphoid structures can predict clinical outcomes of patients with gastric adenocarcinoma.2024Frontiers in immunology免费全文
  30. Remote modulation of WWOX by an intronic variant associated with survival of Chinese gastric cancer patients.2024International journal of cancer
  31. Finding the minimum number of retrieved lymph nodes and negative lymph nodes in gastric cancer surgery: a real-world study.2024International journal of surgery (London, England)免费全文
  32. Clinical comparison of total gastrectomy with single-vessel transection Roux-en-Y reconstruction vs total gastrectomy with conventional Roux-en-Y reconstruction for proximal gastric cancer.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  33. Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer.2024Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  34. C3+ cancer-associated fibroblasts promote tumor growth and therapeutic resistance in gastric cancer via activation of the NF-κB signaling pathway.2024Journal of translational medicine免费全文
  35. Targeting SOX13 inhibits assembly of respiratory chain supercomplexes to overcome ferroptosis resistance in gastric cancer.2024Nature communications免费全文
  36. CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage.2024Oncoimmunology免费全文
  37. Assessing the Value of 68Ga-FAPI PET/CT in Gastric Mucinous Adenocarcinoma or Signet Ring Cell Carcinoma.2024Radiology. Imaging cancer免费全文
  38. Low-dose radiotherapy synergizes with iRGD-antiCD3-modified T cells by facilitating T cell infiltration.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  39. Identifying an immunosenescence-associated gene signature in gastric cancer by integrating bulk and single-cell sequencing data.2024Scientific reports免费全文
  40. Calcipotriol abrogates cancer-associated fibroblast-derived IL-8-mediated oxaliplatin resistance in gastric cancer cells via blocking PI3K/Akt signaling.2023Acta pharmacologica Sinica免费全文
  41. Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial.2023Cancer biology & medicineRCT免费全文
  42. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.2023Cancer immunology, immunotherapy : CII免费全文
  43. Comprehensive analysis of immune subtypes reveals the prognostic value of cytotoxicity and FAP+ fibroblasts in stomach adenocarcinoma.2023Cancer immunology, immunotherapy : CII免费全文
  44. ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer.2023Cancer medicine免费全文
  45. Partial omentectomy maybe practicable for T3 or shallower gastric cancer patients.2023Cancer medicine免费全文
  46. Construction of ovarian metastasis-related immune signature predicting prognosis of gastric cancer patients.2023Cancer medicine免费全文
  47. CD47-targeted immunotherapy unleashes antitumour immunity in Epstein-Barr virus-associated gastric cancer.2023Clinical immunology (Orlando, Fla.)
  48. Novel biogenic preparation of gold nanoparticles decorated on sepiolite clay and evaluation of anti-cancer effect on gastric cancer cell and electrochemical sensing of nitrite.2023Environmental research
  49. Multi-dimension metabolic prognostic model for gastric cancer.2023Frontiers in endocrinology免费全文
  50. SDC2 Stabilization by USP14 Promotes Gastric Cancer Progression through Co-option of PDK1.2023International journal of biological sciences免费全文
  51. Tumor-infiltrating CD226+CD8+ T cells are associated with postoperative prognosis and adjuvant chemotherapeutic benefits in gastric cancer patients.2023Journal of cancer research and clinical oncology免费全文
  52. Hsa_circ_0001944 enhanced GSPT1 expression via sponging miR-498 to promote proliferation and invasion of gastric cancer.2023Journal of clinical laboratory analysis免费全文
  53. Periostin secreted from podoplanin-positive cancer-associated fibroblasts promotes metastasis of gastric cancer by regulating cancer stem cells via AKT and YAP signaling pathway.2023Molecular carcinogenesis
  54. The epigenetic modifier lysine methyltransferase 2C is frequently mutated in gastric remnant carcinoma.2023The journal of pathology. Clinical research免费全文
  55. CPT1C promotes the potential of gastric cancer ovarian metastasis through up-regulating fatty acid oxidation.2022Acta biochimica et biophysica Sinica免费全文
  56. Usefulness of endoscopic ultrasound for acquiring the pathological diagnosis of gastrointestinal lymphoma.2022Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  57. Multiplexed immunofluorescence analysis of CAF-markers, EZH2 and FOXM1 in gastric tissue: associations with clinicopathological parameters and clinical outcomes.2022BMC cancer免费全文
  58. A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma:2022BMC cancer免费全文
  59. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).2022Cancer communications (London, England)RCT免费全文
  60. The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer.2022Cell death & disease免费全文
  61. Integrated DNA and RNA sequencing reveals early drivers involved in metastasis of gastric cancer.2022Cell death & disease免费全文
  62. Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer.2022Clinical immunology (Orlando, Fla.)
  63. Activation of MAT2A-ACSL3 pathway protects cells from ferroptosis in gastric cancer.2022Free radical biology & medicine
  64. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.2022Frontiers in immunology免费全文
  65. Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer.2022Frontiers in immunology免费全文
  66. Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer.2022Frontiers in immunology免费全文
  67. How Can We Better Understand the Gastric Carcinogenesis of Helicobacter pylori?2022Gastroenterology
  68. ASTE1 frameshift mutation triggers the immune response in Epstein-Barr virus-associated gastric cancer.2022Signal transduction and targeted therapy免费全文
  69. The role of nutritional assessment for predicting radiotherapy-induced adverse events in patients with gastric cancer.2022The British journal of radiology免费全文
  70. Novel management indications for conservative treatment of chylous ascites after gastric cancer surgery.2022World journal of gastroenterology免费全文
  71. Prognostic significance of tumor deposits in radically resected gastric cancer: a retrospective study of a cohort of 1915 Chinese individuals.2022World journal of surgical oncology免费全文
  72. Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1.2021Acta biochimica et biophysica Sinica
  73. Combined chemotherapy of platinum and fluorouracil promotes T cell-mediated antitumor immunity.2021Acta biochimica et biophysica Sinica
  74. The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy.2021BMC cancer免费全文
  75. Crocetin suppresses angiogenesis and metastasis through inhibiting sonic hedgehog signaling pathway in gastric cancer.2021Biochemical and biophysical research communications
  76. Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy.2021Cancer immunology, immunotherapy : CII免费全文
  77. Short-form RON (sf-RON) enhances glucose metabolism to promote cell proliferation via activating β-catenin/SIX1 signaling pathway in gastric cancer.2021Cell biology and toxicology免费全文
  78. Value of staging information provided by linear-array endoscopic ultrasound for therapeutic response and prognosis prediction in gastric lymphoma.2021Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  79. Letter to editor: development and internal validation of a diagnostic score for gastric linitis plastic.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  80. Circ-PTPDC1 promotes the Progression of Gastric Cancer through Sponging Mir-139-3p by Regulating ELK1 and Functions as a Prognostic Biomarker.2021International journal of biological sciences免费全文
  81. Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer.2021Journal for immunotherapy of cancer免费全文
  82. NTF4 stimulates the progression of gastric cancer via regulating FOXL1.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  83. Cation Lipid-Assisted PEG6-PLGA Polymer Nanoparticles Encapsulated Knocking Down Long ncRNAs Reverse Non-Coding RNA of Xist Through the Support Vector Machine Model to Regulate the Molecular Mechanisms of Gastric Cancer Cell Apoptosis.2021Journal of biomedical nanotechnology
  84. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.2021Journal of cancer research and clinical oncology免费全文
  85. Involvement of APRIL in Helicobacter pylori-related gastric cancer.2021Journal of cancer research and clinical oncology免费全文
  86. miR-504 Promoted Gastric Cancer Cell Proliferation and Inhibited Cell Apoptosis by Targeting RBM4.2021Journal of immunology research免费全文
  87. Three-year outcomes of the randomized phase III SEIPLUS trial of extensive intraoperative peritoneal lavage for locally advanced gastric cancer.2021Nature communicationsRCT免费全文
  88. Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer.2021Nature communications免费全文
中文论文(未计入)11
  1. [Application and challenges of neoadjuvant therapy in gastric cancer in the immunotherapy era].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Analysis of the safety and efficacy of neoadjuvant immunotherapy combined with chemotherapy for radical resection of locally advanced gastric cancer: a two-center propensity-matched study].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Minimum negative lymph node dissection during radical gastrectomy for gastric cancer: a 22-year, single-center retrospective study].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Rethinking lymph node dissection in gastric cancer during the era of immunotherapy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Analysis of age cut-off and prognosis of early-onset gastric cancer in young patients].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Interpretation of Chinese expert consensus on function-preserving grstrectomy for gastric cancer(2025 edition)].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  8. [Significance and treatment strategies of pathologic complete response after neoadjuvant therapy for gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Analysis on perioperative safety and feasibility of pure single-port laparoscopic distal gastrectomy for gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [The diagnosis and treatment of G3 neuroendocrine tumors according to the new NCCN guideline].2022Zhonghua yi xue za zhi
  11. [Gastric SWI/SNF-complex deficient undifferentiated/rhabdoid carcinoma: a clinicopathological study].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)97
  1. PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy已完成NCT03013010牵头方III期2016-12 启动
  2. A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma正在招募NCT07492615牵头方(推断)II期2026-01 启动
  3. Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ即将招募NCT07912957牵头方(推断)II期2026-11 启动
  4. Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer正在招募NCT07517107牵头方(推断)II期2026-01 启动
  5. Anemia on Sublingual Microcirculation in GDFT邀请入组NCT07583927牵头方(推断)2026-05 启动
  6. A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer即将招募NCT07878221牵头方(推断)II期2026-10 启动
  7. Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer正在招募NCT07194005牵头方(推断)II期2025-09 启动
  8. The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy正在招募NCT07757165牵头方(推断)II期2025-11 启动
  9. The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer正在招募NCT06786169牵头方(推断)2024-09 启动
  10. The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota正在招募NCT07400354牵头方(推断)2024-03 启动
  11. Metronomic Capecitabine in Stage III Gastric Cancer正在招募NCT06313567牵头方(推断)III期2024-03 启动
  12. Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer即将招募NCT06748508牵头方(推断)II期2024-12 启动
  13. Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer正在招募NCT05975749牵头方(推断)II期2023-01 启动
  14. Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer正在招募NCT06121700牵头方(推断)II期2023-01 启动
  15. A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer正在招募NCT06158919牵头方(推断)不分期2023-11 启动
  16. Laparoscopic vs Open Total Gastrectomy for Gastric Cancer正在招募NCT05537129牵头方(推断)不分期2022-10 启动
  17. Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer正在招募NCT04809025牵头方(推断)2021-05 启动
  18. Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma正在招募NCT04997837牵头方(推断)III期2021-07 启动
  19. Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma进行中,不再招募NCT06914687牵头方(推断)II期2025-04 启动
  20. Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer进行中,不再招募NCT07312500牵头方(推断)2025-01 启动
  21. Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma已暂停NCT06728657牵头方(推断)II期2024-07 启动
  22. Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma进行中,不再招募NCT06447636牵头方(推断)II期2024-09 启动
  23. Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC状态不明NCT05982834牵头方(推断)I/II期2023-05 启动
  24. Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)状态不明NCT05893056牵头方(推断)II期2023-06 启动
  25. Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer状态不明NCT05982301牵头方(推断)II期2023-02 启动
  26. Laparoscopic-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric Cancer已完成NCT05541783牵头方(推断)不分期2022-09 启动
  27. Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer已终止NCT05161572牵头方(推断)II期2021-09 启动
  28. Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer状态不明NCT05095636牵头方(推断)II期2021-03 启动
  29. Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma状态不明NCT05111444牵头方(推断)II期2021-12 启动
  30. A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites状态不明NCT03475615牵头方(推断)III期2018-03 启动
  31. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)已完成NCT03399110牵头方(推断)III期2018-01 启动
  32. The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer已完成NCT02395640牵头方(推断)III期2015-03 启动
  33. Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer状态不明NCT02072317牵头方(推断)II期2013-11 启动
  34. Neoadjuvant Chemotherapy Plus Chemoradiation in Patients With Potentially Resectable Gastric Carcinoma状态不明NCT02024217牵头方(推断)II期2012-03 启动
  35. Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Quality of Life in Patients Undergoing Total Gastrectomy状态不明NCT01697943牵头方(推断)III期2012-05 启动
  36. A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC状态不明NCT01963702牵头方(推断)II期2012-08 启动
  37. Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer已完成NCT00970138牵头方(推断)II/III期2009-06 启动
  38. Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer状态不明NCT00992199牵头方(推断)II期2009-08 启动
  39. Study of Cetuximab to Treat Gastric Cancer已完成NCT00699881牵头方(推断)II期2008-05 启动
  40. Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer已暂停NCT00568529牵头方(推断)II期2007-10 启动
  41. Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer已终止NCT00595985牵头方(推断)II期2007-07 启动
  42. Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer已完成NCT00595972牵头方(推断)II期2007-11 启动
  43. Study of Weekly DCF to Treat Advanced Gastric Cancer已终止NCT00568971牵头方(推断)II期2007-04 启动
  44. Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC已完成NCT00767377牵头方(推断)II期2007-05 启动
  45. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  46. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  47. TR115 in ARID1A-Mutated Advanced Solid Tumors即将招募NCT07793318研究中心II期2026-09 启动
  48. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma即将招募NCT07902596研究中心2026-10 启动
  49. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  50. A IIT Study of 177Lu-DOTA-SNA040正在招募NCT07595237研究中心早期I期2025-11 启动
  51. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)正在招募NCT06760819研究中心II期2025-02 启动
  52. A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors即将招募NCT07036185研究中心I期2025-06 启动
  53. HS-10502 Combination Treatment in Patients With Advanced Solid Tumors正在招募NCT06769425研究中心I期2025-05 启动
  54. Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer正在招募NCT07366528研究中心III期2025-12 启动
  55. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  56. Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study正在招募NCT06679244研究中心不分期2024-12 启动
  57. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  58. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread正在招募NCT06324357研究中心I/II期2024-06 启动
  59. Early Detection and Post-operative Monitoring of Gastric Cancer正在招募NCT06232395研究中心2024-02 启动
  60. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer正在招募NCT06128252研究中心不分期2024-09 启动
  61. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)正在招募NCT06469944研究中心I/II期2024-09 启动
  62. A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors正在招募NCT07923214研究中心I期2024-07 启动
  63. Post-operative Monitoring of Gastric Cancer正在招募NCT07026240研究中心2024-02 启动
  64. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure正在招募NCT06081647研究中心不分期2023-12 启动
  65. A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors正在招募NCT06131840研究中心I期2023-11 启动
  66. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  67. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.进行中,不再招募NCT06116136研究中心I/II期2024-08 启动
  68. EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer已撤回NCT05411679研究中心II期2023-04 启动
  69. HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer状态不明NCT05246982研究中心II期2022-03 启动
  70. Development of Free DNA Multi-target Methylated PCR for Auxiliary Diagnosis of Gastric Cancer已完成NCT05336058研究中心2022-02 启动
  71. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  72. IMM2902 in Patients With Advanced Solid Tumors Expressing HER2状态不明NCT05805956研究中心I/II期2022-02 启动
  73. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  74. Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)进行中,不再招募NCT05382364研究中心I期2022-06 启动
  75. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs已完成NCT04852679研究中心III期2021-05 启动
  76. Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE进行中,不再招募NCT04919226研究中心III期2021-12 启动
  77. SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies已终止NCT05039944研究中心II期2021-11 启动
  78. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  79. A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.状态不明NCT04435652研究中心II/III期2020-07 启动
  80. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  81. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  82. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  83. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  84. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers状态不明NCT03468712研究中心不分期2018-03 启动
  85. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  86. Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer已完成NCT03619681研究中心I期2018-09 启动
  87. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  88. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810状态不明NCT03260179研究中心I期2017-08 启动
  89. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  90. A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer已完成NCT02426034研究中心IV期2015-05 启动
  91. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  92. A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer已完成NCT02252913研究中心I期2014-09 启动
  93. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动
  94. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer已完成NCT01774786研究中心III期2013-06 启动
  95. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动
  96. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer已终止NCT01641939研究中心II/III期2012-09 启动
  97. Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer已完成NCT01512745研究中心III期2011-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 2.9%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 1120242025: 002025

上海有 15 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.3%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 2220242025: 112025

上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文6
  1. Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas.2025Biomolecules
  2. Osteosarcoma-targeted Cu and Ce based oxide nanoplatform for NIR II fluorescence/magnetic resonance dual-mode imaging and ros cascade amplification along with immunotherapy.2024Journal of nanobiotechnology
  3. Gastrointestinal Ewing Sarcoma: A Clinicopathological and Molecular Genetic Analysis of 25 Cases.2024The American journal of surgical pathology
  4. Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis ?2023European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  5. LncRNA-EWSAT1 promotes hepatocellular carcinoma metastasis via activation of the Src-YAP signaling axis.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  6. KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.2021Biochemical and biophysical research communications
早期论文(2016–2020 年)7
  1. Growth hormone receptor promotes osteosarcoma cell growth and metastases.2020FEBS open bio
  2. Silencing of synaptotagmin 7 regulates osteosarcoma cell proliferation, apoptosis, and migration.2020Histology and histopathology
  3. Metabolism of Reactive Oxygen Species in Osteosarcoma and Potential Treatment Applications.2019Cells
  4. Knockdown of Kinesin Family 15 Inhibits Osteosarcoma through Suppressing Cell Proliferation and Promoting Cell Apoptosis.2019Chemotherapy
  5. Oridonin inhibits the proliferation, migration and invasion of human osteosarcoma cells via suppression of matrix metalloproteinase expression and STAT3 signalling pathway.2019Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  6. HOTAIR promotes osteosarcoma development by sponging miR-217 and targeting ZEB1.2019Journal of cellular physiology
  7. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.2018European journal of pharmacology

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头

上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    A Study of HQP1351 in Patients With GIST or Other Solid Tumors
    分期
    I期
    开始
    2018-07
    登记号
    NCT03594422

    年龄 12 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、广州、武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
早期论文(2016–2020 年)6
  1. Development and validation of a nomogram based on CT images and 3D texture analysis for preoperative prediction of the malignant potential in gastrointestinal stromal tumors.2020Cancer imaging : the official publication of the International Cancer Imaging Society
  2. A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.2020Cancer medicine
  3. Gastric sub-epithelial tumors: identification of gastrointestinal stromal tumors using CT with a practical scoring method.2019Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  4. Differentiation of Gastric Schwannoma From Gastric Gastrointestinal Stromal Tumor With Dual-Phase Contrast-Enhanced Computed Tomography.2019Journal of computer assisted tomography
  5. MiR-374b Promotes Proliferation and Inhibits Apoptosis of Human GIST Cells by Inhibiting PTEN through Activation of the PI3K/Akt Pathway.2018Molecules and cells
  6. Involvement of Bmi-1 gene in the development of gastrointestinal stromal tumor by regulating p16Ink4A/p14ARF gene expressions: An in vivo and in vitro study.2017Pathology, research and practice
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动
  2. A Study of HQP1351 in Patients With GIST or Other Solid Tumors正在招募NCT03594422研究中心I期2018-07 启动
  3. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)已完成NCT04282980研究中心II期2020-04 启动
  4. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib已完成NCT04633122研究中心II期2020-11 启动
  5. A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor已完成NCT04254939研究中心I/II期2019-08 启动
  6. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST已完成NCT03465722研究中心III期2018-03 启动
  7. A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST状态不明NCT02776878研究中心不分期2016-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 2.5%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

上海有 15 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科病理/检验科
牵头的论文4
  1. Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas.2025Biomolecules
  2. Gastrointestinal Ewing Sarcoma: A Clinicopathological and Molecular Genetic Analysis of 25 Cases.2024The American journal of surgical pathology
  3. Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis ?2023European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  4. LncRNA-EWSAT1 promotes hepatocellular carcinoma metastasis via activation of the Src-YAP signaling axis.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)已终止NCT00568464牵头方(推断)II期2007-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头

上海有 9 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
    分期
    I期
    开始
    2024-05
    登记号
    NCT06445803

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、南昌

  2. 正在招募
    Phase Ib Clinical Study of Keynatinib
    分期
    I期
    开始
    2020-09
    登记号
    NCT04807881

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京、成都

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL正在招募NCT06445803研究中心I期2024-05 启动
  2. Phase Ib Clinical Study of Keynatinib正在招募NCT04807881研究中心I期2020-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

上海有 9 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
牵头的论文1
  1. A one-stop approach to diagnosing hereditary colorectal cancer in the Chinese population.2023Journal of gastroenterology and hepatology
中文论文(未计入)1
  1. [A case of familial adenomatous polyposis in an adult male with Lynch-like syndrome].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
早期论文(2016–2020 年)1
  1. [Advance in research on the correlation between genotypes of susceptible mutations and clinical phenotype of familial adenomatous polyposis].2017Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

复旦大学附属肿瘤医院

Fudan University Shanghai Cancer Center

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Shanghai Cancer Center; Fudan University Cancer Hospital; Fudan University Shanghai Cancer Centre; Fudan University Shanghai Cancer Centers; Fudan University Shanghai Cancer Center Xiamen Hospital; Cancer Hospital of Fudan University; Shanghai Cancer Hospital; and Fudan University Shanghai Cancer Center

提出更正下载数据